Bladder Cancer - Results from #320

REVIEW UroToday

Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multi-Site Single-Institution Prospective Study. June 13, 2024

An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer. June 13, 2024

Avelumab maintenance therapy for node-positive muscle invasive bladder cancer: a report of two cases. June 13, 2024

ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol. June 12, 2024

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. June 12, 2024

Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment. June 12, 2024

Prognostic Value of Longitudinal ctDNA in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy - Expert Commentary June 11, 2024

Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy. June 11, 2024

Pediatric urothelial cancer: a cross-sectional descriptive analysis of the National Cancer Database. June 11, 2024

Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer. June 10, 2024

The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guérin in Treating Nonmuscle-Invasive Bladder Cancer. June 10, 2024

From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. June 7, 2024

No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized t June 7, 2024

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC June 7, 2024

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial June 6, 2024

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. June 6, 2024

Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer. June 6, 2024

Predictive Biomarkers in Sarcomatoid and Rhabdoid Bladder Urothelial Carcinoma - Expert Commentary June 5, 2024

International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity. June 5, 2024

Efficiency of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer: An umbrella review. June 5, 2024

Page 17 of 517